Point72 Asia (Singapore) Pte. Ltd. Allovir, Inc. Transaction History

Point72 Asia (Singapore) Pte. Ltd.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.4 - $1.01 $1,349 - $3,407	-3,374 Reduced 11.15%	26,887 $11.3 Million
Q3 2024 Nov 14, 2024	SELL	$0.7 - $0.82 $32,211 - $37,733	-46,017 Reduced 60.33%	30,261 $24.5 Million
Q2 2024 Aug 14, 2024	BUY	$0.72 - $0.82 $54,920 - $62,547	76,278 New	76,278 $55.2 Million

727K

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $913M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Point72 Asia (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

Stay updated on Point72 Asia (Singapore) Pte. Ltd. with notifications on news.